JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Endocrinology (1989) 122, 331-340    DOI: 10.1677/joe.0.1220331
© 1989 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarke, R.
Right arrow Articles by Lippman, M. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Clarke, R.
Right arrow Articles by Lippman, M. E.

The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer

 R. Clarke, N. Brünner, E. W. Thompson, P. Glanz, D. Katz, R. B. Dickson and M. E. Lippman

Among the processes contributing to the progressive acquisition of the highly malignant phenotype in breast cancer are ovarian-independent growth, antioestrogen resistance and increased metastatic potential. We have previously observed that increased invasiveness and development of ovarian-independent growth occur independently. In an attempt to define the inter-relationships between these processes further, we have compared the phenotypes of ovarian-independent, invasive and antioestrogen-resistant sublines of the ovarian-dependent human breast cancer cell line MCF-7. Cells acquiring ovarian-independent growth can retain sensitivity to anti-oestrogens. One clone of MCF-7 cells selected for stable antioestrogen resistance has become non-tumorigenic but its invasive potential remains unaltered. Thus, acquisition of some characteristics of the progressed phenotype can occur independently. This phenomenon of independent parameters in phenotypic progression could partly explain the considerable intra- and intertumour heterogeneity characteristic of breast tumours.

Journal of Endocrinology (1989) 122, 331–340




This article has been cited by other articles:


Home page
 Toxicol SciHome page
M. G. Goodin, K. C. Fertuck, T. R. Zacharewski, and R. J. Rosengren
Estrogen Receptor-Mediated Actions of Polyphenolic Catechins in Vivo and in Vitro
Toxicol. Sci., October 1, 2002; 69(2): 354 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sterin, J. S. Cohen, Y. Mardor, E. Berman, and I. Ringel
Levels of Phospholipid Metabolites in Breast Cancer Cells Treated with Antimitotic Drugs: A 31P-Magnetic Resonance Spectroscopy Study
Cancer Res., October 1, 2001; 61(20): 7536 - 7543.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. R. James, T. C. Skaar, R. Y. Lee, A. MacPherson, J. A. Zwiebel, B. S. Ahluwalia, F. Ampy, and R. Clarke
Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cells in Vitro and in Vivo
Endocrinology, April 1, 2001; 142(4): 1497 - 1505.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Bratland, K. Risberg, G. M. Mælandsmo, K. B. Gützkow, O. E. Olsen, A. Moghaddam, M.-y. Wang, C. M. Hansen, H. K. Blomhoff, J. P. Berg, et al.
Expression of a Novel Factor, com1, Is Regulated by 1,25-Dihydroxyvitamin D3 in Breast Cancer Cells
Cancer Res., October 1, 2000; 60(19): 5578 - 5583.
[Abstract] [Full Text]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the Society for Endocrinology.